Bio-Rad

Sales in the life science segment grew 5 percent due in part to sales of the firm's Digital Droplet PCR system and reagents. 

The legal battle began last fall when LabCorp subsidiary Esoterix and Johns Hopkins University sued Myriad alleging infringement of four patents. 

The firm's topline performance for the full year was also higher than previous guidance provided by the company and analyst estimates.

A jury in Northern California has found that Sanford Wadler was wrongfully terminated and awarded him back pay and punitive damages.

The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.

Terms of the deal have not been disclosed, but the firms expect to finalize the acquisition in the first quarter of 2017.

Systems will ship in early February and include droplet-based library prep and analytics functionalities.

Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.

The Norwegian microbiome-focused clinical diagnostics company has ceded commercialization rights in certain undisclosed territories to Bio-Rad as part of the deal.

The firm reported revenues of $508.7 million, thanks largely to an 18 percent increase in sales from the company's life science segment. 

Pages

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.